Takeshi Masuda1, Y U Wakabayashi2, Taku Nakashima3, Yoshifumi Nishimura4, Kiyofumi Shimoji2, Kakuhiro Yamaguchi3, Shinjiro Sakamoto3, Yasushi Horimasu3, Shintaro Miyamoto3, Tadashi Senoo5, Hiroshi Iwamoto2, Shinichiro Ohshimo6, Kazunori Fujitaka2, Hironobu Hamada7, Noboru Hattori2. 1. Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan; ta-masuda@hiroshima-u.ac.jp. 2. Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan. 3. Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. 4. Department of Respiratory Internal Medicine, Higashihiroshima Medical Center, Higashihiroshima, Japan. 5. Department of Respiratory Internal Medicine, Kure Medical Center, Kure, Japan. 6. Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 7. Department of Physical Analysis and Therapeutic Sciences, Hiroshima University, Hiroshima, Japan.
Abstract
BACKGROUND/AIM: The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR- tyrosine kinase inhibitors (TKI)-treated vs. BSC patients. PATIENTS AND METHODS: Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study. RESULTS: Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKI-treated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter. CONCLUSION: Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC.
BACKGROUND/AIM: The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR- tyrosine kinase inhibitors (TKI)-treated vs. BSC patients. PATIENTS AND METHODS: Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study. RESULTS: Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKI-treated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter. CONCLUSION: Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC.